Siplizumab
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells[1].
Product Specifications
CAS Number
288392-69-8
Product Name Alternative
MEDI-507
UNSPSC
12352203
Target
CD2
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/siplizumab.html
Purity
99.83
Solubility
10 mM in DMSO
Smiles
[Siplizumab]
Molecular Weight
(146.25 kDa)
References & Citations
[1]Binder C, et, al. Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro. Front Immunol. 2020 Nov 11;11:592553.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC401354 20 µg
Melatonin Related Receptor (GPR50) (NM_004224) Human Over-expression Lysate
Sign In for Pricing
View Details 
